Articaine Gargle Trial for Upper Endoscopy Patient Tolerability

A 2014-2015 randomized, double-blind, placebo-controlled trial by Niklas Mattila assessed a novel articaine gargle for upper endoscopy. The study involved 90 adult patients undergoing gastroscopy without sedation across three treatment groups. Patient tolerability, satisfaction, endoscopist ratings, and vital signs were collected via questionnaires and monitoring.

Use Cases

• Analyze the relationship between treatment group (articaine 10 mg/ml, 20 mg/ml, placebo) and patient tolerability scores from questionnaires.
• Compare procedural completion rates and endoscopist satisfaction ratings across the three different treatment arms.
• Model the correlation between recorded patient pulse and oxygen saturation during the procedure and their reported satisfaction levels.
• Investigate the impact of early trial termination on the statistical power to detect differences in primary outcomes like patient tolerance.

Strengths

• Data from a randomized, double-blind, placebo-controlled trial design with 90 patient records.
• Includes multiple measurement types: patient questionnaires, endoscopist ratings, and physiological data (pulse, oxygen saturation).

Limitations

• Small sample size of 90 patients, with the trial terminated before reaching its originally intended target.
• Findings showed no statistically significant improvement from the intervention, limiting predictive modeling potential.
• Geographic and demographic scope of the patient population is not specified, which may limit generalizability.

Provenance

Source

Figshare deposit by author Niklas Mattila, associated with clinical trial NCT02105090.

Collection Method

Data collected via patient and endoscopist questionnaires and physiological monitoring during a randomized controlled trial.

Time Range

Clinical trial period (likely 2014-2015 based on registry date).

Freshness

Last updated on the platform in 2026, but the underlying clinical trial (NCT02105090) was conducted earlier.